In Reply We read with interest the response of Kovarik et al to our consensus statement.1 The scope of our effort in developing the Checklist for Evaluation of Image-Based Artificial Intelligence Reports in Dermatology consensus guidelines was restricted to technical aspects of the development and reporting of image-based artificial intelligence (AI) in dermatology. We agree that questions associated with patient consent are crucial, but our assessment is that further research and broader participation are required to develop formal consent guidelines. Such efforts should consider existing regulatory and legal requirements, which vary geographically, as well as ethical issues. We would point out that the General Data Protection Regulation of Europe, which is among the more stringent legal frameworks that establish guidelines for collecting and processing personal information, allows sharing of deidentified data for AI use.2,3 We believe that formal research on patient preferences and potential harms is needed to inform the answers to the questions of Kovarik et al. We, among others, are actively engaged in conducting such research, and we strongly endorse the development of guidelines around patient consent for images used in AI.

Roxana Daneshjou, MD, PhD
Veronica Rotemberg, MD, PhD
for the International Skin Imaging Collaboration Artificial Intelligence Working Group

Author Affiliations: Department of Dermatology, Stanford School of Medicine, Redwood City, California (Daneshjou); Department of Biomedical Data Science, Stanford School of Medicine, Stanford, California (Daneshjou); Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York (Rotemberg).

Corresponding Author: Veronica Rotemberg, MD, PhD, 530 E 74th St, 9th Flr, Dermatology, New York, NY 10021 (rotembev@mskcc.org).

Published Online: April 13, 2022. doi:10.1001/jamadermatol.2022.0108

Conflict of Interest Disclosures: Dr Daneshjou reported personal fees from DWA, Pfizer, and VisualDX as well as grants from UCB outside the submitted work; in addition, Dr Daneshjou has a patent for US Provisional Patent Application 63/251,527 pending. Dr Rotemberg reported nonfinancial support from Inhibit Brands Inc outside the submitted work.

The International Skin Imaging Collaboration Artificial Intelligence Working Group: Catarina Barata, Instituto Superior Tecnico, Brigid Betz-Stablein, The University of Queensland, M. Emre Celebi, University of Central Arkansas, Noel Codella, Microsoft, Marc Combalia, Universtitat de Barcelona, Pascale Guitera, University of Sydney and Royal Prince Alfred Hospital, David Gutman, Emory University, Allan Halpern, Memorial Sloan Kettering Cancer Center, Brian Helba, Kitware Inc, Harald Kittler, Medical University of Vienna, Kivanc Kose, Memorial Sloan Kettering Cancer Center, Konstantinos Liopyris, University of Athens Medical School, Josep Malvehy, Universtitat de Barcelona, Han Seung Seog, IDerma Inc, H. Peter Soyer, The University of Queensland, Eric R. Tkaczyk, Tennessee Valley Healthcare System and Vanderbilt University, and Philipp Tschantl, Medical University of Vienna.


CORRECTION

Error in Author Name: The Review titled, “Identification of Biomarkers and Critical Evaluation of Biomarker Validation in Hidradenitis Suppurativa: A Systematic Review,” published in the March 2022 print issue, included an error in the byline. The eighth author’s name, which appeared as “Nisha Chandran Suyien, MD,” has been corrected to “Nisha Suyien Chandran, MD.” This article has been corrected online.